In vitro efficacy of six cephalosporins tested against Enterobacteriaceae isolated at 38 North American medical centres participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998

International Journal of Antimicrobial Agents

Volumn 15, Issue 2, 2000, Pages 111-118

  Jones, Ronald N ^a   Jenkins, Stephen G ^b   Hoban, Daryl J ^c   Pfaller, Michael A ^a   Ramphal, Reuben ^d  

^a Medical Microbiology Division   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Lactamase; Cefepime; Ceftazidime; Enterobacteriacae

Indexed keywords

CEFAZOLIN; CEFEPIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE;

ANTIBIOTIC THERAPY; ARTICLE; DILUTION; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; ENTEROBACTER; ESCHERICHIA COLI; GEOGRAPHIC DISTRIBUTION; INTERNATIONAL COOPERATION; KLEBSIELLA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL;

BETA-LACTAMASES; CEPHALOSPORINS; CITROBACTER; DRUG RESISTANCE, MICROBIAL; ENTEROBACTER; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MULTICENTER STUDIES; NORTH AMERICA; SERRATIA MARCESCENS; SPECIES SPECIFICITY;

EID: 0034120323     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00152-7     Document Type: Article

References (20)

1. Jones R.N., Baquero F., Privitera P., Inoue M., Weidemann B. Inducible β-lactamase-mediated resistance to third-generation cephalosporins. Clin. Microbiol. Infect. 3:(Suppl. 1):1997;S7-20.
2. Pfaller M.A., Jones R.N., Marshall S.A., et al. nducible Amp C β-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). Diagn. Microbiol. Infect. Dis. 2:(8):1997;211-219.
3. Nordmann P. Trends in β-lactam resistance among Enterobacteriaceae. Clin. Infect. Dis. 27:(Suppl. 1):1998;S100-106.
4. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in pediatric intensive care units in the United States. Pediatrics 103: e39 Available at: http://www.pediatrics.org/cgi/content/full/103/4/e39 . Accessed October 13, 1999.
5. Richards M.J., Edwards J.R., Culver D.H., Gaynes R.P. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit. Care Med. 27:1999;887-892.
6. Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance System Antimicrobial Resistance Surveillance Report. Available at: www.cdc.gov/ncidod/hip/NNIS/AR_Surv1198.htm. Updated February 24, 1999. Accessed October 20, 1999.
7. Chow J.W., Fine M.J., Shales D.M., et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann. Intern. Med. 115:1991;585-590.
8. Pfaller M.A., Jones R.N., Doern G.V., Kugler K. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob. Agents Chemother. 42:1998;1762-1770.
9. Methods for Dilution Antimicrobial Tests for Bacteria That Grow Aerobically: Approved Standard M7-A4. 4th ed. 1997;Nat Com Clin Lab Stud, Wayne, PA.
10. Performance Standards for Antimicrobial Susceptibility Testing; 9th Informational Supplement M100-S9. 1999;Nat Com Clin Lab Stud, Wayne, PA.
11. Cormican M.G., Marshall S.A., Jones R.N. Detection of extended-spectrum beta-lactamase (ESBL)-producing strains by the Etest ESBL screen. J. Clin. Microbiol. 34:1996;1880-1884.
12. Edmond M.B., Wallace S.E., McClish D.K., Pfaller M.A., Jones R.N., Wenzel R.P. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin. Infect. Dis. 29:1999;239-244.
13. Jones R.N., Pfaller M.A., Doern G.V., Erwin M.E., Hollis R.J. Antimicrobial activity and spectrum investigation of eight broad-spectrum β-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Diagn. Microbiol. Infect. Dis. 30:1998;215-228.
14. Thauvin-Eliopoulos C., Tripodi M.F., Moellering R.C. Jr, Eliopoulos G.M. Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 41:1997;1052-1057.
15. Sanders W.E. Jr, Tenney J.H., Kessler R.E. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin. Infect. Dis. 23:1996;454-461.
16. Itokazu G.S., Quinn J.P., Bell-Dixon C., Kahan F.M., Weinstein R.A. Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program. Clin. Infect. Dis. 23:1996;779-784.
17. Burwen D.R., Banerjee S.N., Gaynes R.P. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. J. Infect. Dis. 170:1996;1622-1625.
18. Fridkin S.K., Steward C.D., Edwards J.R., et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE phase 2. Clin. Infect. Dis. 29:1999;245-252.
19. Diekma D.J., Pfaller M.A., Jones R.N., et al. Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin. Infect. Dis. 29:1999;595-607.
20. Jones R.N. Important and emerging β-lactamase-mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn. Microbiol. Infect. Dis. 31:1998;461-466.